332 related articles for article (PubMed ID: 20187017)
21. Determining patient selection tool and response predictor for outpatient 30 mCi radioiodine ablation dose in non-metastatic differentiated thyroid carcinoma: a Japanese perspective.
Higuchi T; Achmad A; Binh DD; Bhattarai A; Tsushima Y
Endocr J; 2018 Mar; 65(3):345-357. PubMed ID: 29343651
[TBL] [Abstract][Full Text] [Related]
22. [Radioiodine therapy in differentiated thyroid gland carcinoma].
Schicha H; Dietlein M
Zentralbl Chir; 1997; 122(4):266-73. PubMed ID: 9221637
[TBL] [Abstract][Full Text] [Related]
23. [Prospective therapy study in differentiated thyroid carcinoma].
Gemsenjäger E; Heitz P; Martina B
Schweiz Med Wochenschr; 1995 Nov; 125(46):2226-36. PubMed ID: 8525342
[TBL] [Abstract][Full Text] [Related]
24. [Follow-up of papillary and follicular thyroid cancer--when and where?].
Mäenpää HO; Välimäki MJ
Duodecim; 2010; 126(20):2424-30. PubMed ID: 21125756
[TBL] [Abstract][Full Text] [Related]
25. A randomized clinical trial comparing 50mCi and 100mCi of iodine-131 for ablation of differentiated thyroid cancers.
Zaman Mu; Toor R; Kamal S; Maqbool M; Habib S; Niaz K
J Pak Med Assoc; 2006 Aug; 56(8):353-6. PubMed ID: 16967785
[TBL] [Abstract][Full Text] [Related]
26. Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment.
Bonnet S; Hartl D; Leboulleux S; Baudin E; Lumbroso JD; Al Ghuzlan A; Chami L; Schlumberger M; Travagli JP
J Clin Endocrinol Metab; 2009 Apr; 94(4):1162-7. PubMed ID: 19116234
[TBL] [Abstract][Full Text] [Related]
27. Management of thyroid papillary carcinoma with radioiodine in a patient with end stage renal disease on hemodialysis.
Mello AM; Isaacs R; Petersen J; Kronenberger S; McDougall IR
Clin Nucl Med; 1994 Sep; 19(9):776-81. PubMed ID: 7982310
[TBL] [Abstract][Full Text] [Related]
28. Is radioiodine ablation necessary for patients with low-risk papillary thyroid carcinoma and tumor >4 cm?
Rosario PW
Eur J Surg Oncol; 2017 Sep; 43(9):1802-1803. PubMed ID: 28743373
[No Abstract] [Full Text] [Related]
29. [Long-term course in differentiated thyroid gland carcinoma].
Rösler H; Birrer A; Lüscher D; Kinser J
Schweiz Med Wochenschr; 1992 Nov; 122(48):1843-57. PubMed ID: 1462145
[TBL] [Abstract][Full Text] [Related]
30. [Combined surgical and radiotherapeutic treatment of papillary and follicular thyroid carcinoma].
Jadoul D; Glanzmann C; Lütolf U; Hahnloser P
Helv Chir Acta; 1976 Dec; 43(5-6):635-40. PubMed ID: 826510
[No Abstract] [Full Text] [Related]
31. Postoperative management of differentiated thyroid cancer.
Sabet A; Kim M
Otolaryngol Clin North Am; 2010 Apr; 43(2):329-51, viii-ix. PubMed ID: 20510717
[TBL] [Abstract][Full Text] [Related]
32. Current perspectives on papillary carcinoma of the thyroid gland.
Chiu MK; Sherry RM; Wei JP
J Med Assoc Ga; 1992 Aug; 81(8):442-4. PubMed ID: 1512532
[TBL] [Abstract][Full Text] [Related]
33. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients.
Hay ID; Thompson GB; Grant CS; Bergstralh EJ; Dvorak CE; Gorman CA; Maurer MS; McIver B; Mullan BP; Oberg AL; Powell CC; van Heerden JA; Goellner JR
World J Surg; 2002 Aug; 26(8):879-85. PubMed ID: 12016468
[TBL] [Abstract][Full Text] [Related]
34. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer.
Sawka AM; Brierley JD; Tsang RW; Thabane L; Rotstein L; Gafni A; Straus S; Goldstein DP
Endocrinol Metab Clin North Am; 2008 Jun; 37(2):457-80, x. PubMed ID: 18502337
[TBL] [Abstract][Full Text] [Related]
35. [Diagnosis, treatment and follow-up in the case of differentiated thyroid cancer].
Lind P; Igerc I; Kohlfürst S
Wien Med Wochenschr; 2005 Oct; 155(19-20):429-35. PubMed ID: 16424998
[TBL] [Abstract][Full Text] [Related]
36. Radioiodine and radiotherapy in the management of thyroid cancers.
Simpson WJ
Otolaryngol Clin North Am; 1990 Jun; 23(3):509-21. PubMed ID: 1694984
[TBL] [Abstract][Full Text] [Related]
37. An evaluation of the value of first thyroglobulin determination in the diagnostics of metastases immediately following differentiated thyroid carcinoma surgery.
Makarewicz J; Adamczewski Z; Rutkowski A; Mikosiński S; Knapska-Kucharska M; Gonerska-Szadkowska A; Oszukowska L; Karwowska A; Lewiński A
Endokrynol Pol; 2006; 57(4):370-3. PubMed ID: 17006838
[TBL] [Abstract][Full Text] [Related]
38. Low-risk differentiated thyroid carcinoma patients still deserve I-131 remnant ablation after total thyroidectomy.
Verburg FA; Luster M
Minerva Chir; 2010 Feb; 65(1):95-100. PubMed ID: 20212421
[TBL] [Abstract][Full Text] [Related]
39. I-123-guided excision of metastatic papillary thyroid cancer.
Khandelwal S; Sener SF; Purdy L; Perlman RM
J Surg Oncol; 2007 Aug; 96(2):173-5. PubMed ID: 17443733
[TBL] [Abstract][Full Text] [Related]
40. Incidental multifocal papillary microcarcinomas of the thyroid: is subtotal thyroidectomy combined with radioiodine ablation enough?
Dietlein M; Luyken WA; Schicha H; Larena-Avellaneda A
Nucl Med Commun; 2005 Jan; 26(1):3-8. PubMed ID: 15604941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
